Adjuvant topical chemotherapy with cisplatin in superficial bladder cancer
Flamm, J.; Grof, F.
Der Urologe. Ausg. a 25(1): 48-50
1986
ISSN/ISBN: 0340-2592 PMID: 3962044 Document Number: 284872
During a period of 6 weeks we applied a weekly dosage of 50 mg of cis-platinum as an intravesical instillation treatment to 30 patients with superficial carcinomas of the urinary bladder. Prior to this treatment these patients had undergone a transurethral differentiated resection of their tumours by multiple biopsies (mapping). Persistent tumours were found in 3 patients (10%). After an observation time of 22 months the relapse rate in pTa tumours was 5.5 and in pT1 tumours 7.6.
Document emailed within 1 workday
Related Documents
Morales, A. 1978: Adjuvant immunotherapy in superficial bladder cancer National Cancer Institute Monograph 49: 315-319Colombo, R. 2006: Only an overall 15% net benefit emerges in favour of adjuvant intravesical chemotherapy when compared to transurethral resection alone for the prevention of recurrences of superficial bladder tumors European Urology 50(2): 233-234
Moriyama, M.; Kubota, Y.; Miura, T.; Shuin, T.; Noguchi, S. 1983: The effect of intravesical chemotherapy on superficial urinary bladder cancer Hinyokika Kiyo. Acta Urologica Japonica 29(3): 351-355
Raghavan, D.; Pearson, B.; Watt, W.H.; Mameghan, H.; Langdon, P.; Eisinger, D.; Wines, R. 1991: Cytotoxic chemotherapy for advanced bladder cancer: cisplatin-containing regimens Seminars in Oncology 18(1 Suppl 3): 56-63
Scher, H.I. 1990: Chemotherapy for invasive bladder cancer: neoadjuvant versus adjuvant Seminars in Oncology 17(5): 555-565
Flüchter, S.H.; Harzmann, R.; Erdmann, D.; Bichler, K.H. 1982: Recurrence rate in adjuvant local chemotherapy of bladder cancer with mitomycin C Helvetica Chirurgica Acta 49(3-4): 349-352
Ichihashi, H.; Yamauchi, M.; Watanabe, T.; Takagi, H.; Kondo, T. 1988: Prospective adjuvant chemotherapy of mitomycin C plus HCFU for colorectal cancer (2d report)--6-year survival after surgery: Tokai Cooperative Study Group of Surgical Adjuvant Chemotherapy Gan no Rinsho. Japan Journal of Cancer Clinics 34(4): 451-456
Takashi, M.; Murase, T.; Aota, Y.; Nagai, T.; Kinjo, T.; Sabashi, M.; Shimoji, T.; Miyake, K.; Hamajma, N.; Mizuno, S. 1988: Multivariate evaluation of survival factors and postoperative adjuvant chemotherapy in patients with bladder cancer treated by radical cystectomy Hinyokika Kiyo. Acta Urologica Japonica 34(8): 1377-1381
Kotake, T.; Koyanagi, T.; Akaza, H.; Shimazaki, J.; Ito, H.; Hosaka, M.; Okajima, E.; Saito, Y.; Miyanaga, N.; Kuroda, M.; Hirao, Y. 1998: Results of clinical study with epirubicin hydrochloride injectable solution for superficial bladder cancer. IMI28 Injectable Solution Study Group for Superficial Bladder Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 25(8): 1189-1195
Bollack, C.; Jacqmin, D.; Splinter, T.A.; De Pauw, M. 1988: Non-adjuvant chemotherapy of bladder neoplasms stage T3-4 using NO-x and MO. Preliminary results of the urogenital study group of the European Organization for Research and Treatment of Cancer Casopis Lekaru Ceskych 127(35): 1098-1100
Dernell, W.S.; Withrow, S.J.; Straw, R.C.; Lafferty, M.H. 1997: Adjuvant chemotherapy using cisplatin by subcutaneous administration In Vivo 11(4): 345-350
Yoshida, K.; Takahashi, T.; Nakame, Y.; Saitoh, H.; Horiuchi, S.; Kaneoya, F.; Negishi, T. 1987: Bladder instillation of verapamil as a means of enhancing the efficacy of chemotherapy in superficial bladder carcinoma: influence of bladder instillation of verapamil on the cardiovascular system Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(2): 506-510
Iturralde Codina, A.; Beyríe Tamayo, W.; Gozá León, F.; Muñoz, Y.I. 2004: Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes Archivos Espanoles de Urologia 57(6): 606-618
Makhnova, E.V. 2003: Combination chemotherapy with Hemzar (gemcitabine) and cisplatin for relapsing and cisplatin-resistant ovarian cancer Voprosy Onkologii 49(1): 60-65
Matsumura, Y. 1989: Intravesical chemotherapy of superficial bladder tumors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(2): 193-198
Punga-Maole, M.L.; Hubert, J.; Mangin, P. 1995: Bladder retraction, a complication of chemoprophylaxis of superficial bladder cancer using intravesical mitomycin C. Apropos of a case and review of the literature Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 5(4): 580-585
Le Duc, A. 1989: Chemotherapy by endovesical instillation. Its value in the treatment of superficial tumors of the bladder Pathologie-Biologie 37(9): 1072
Roth, J.A.; Pass, H.I.; Flanagan, M.M.; Graeber, G.M.; Rosenberg, J.C.; Steinberg, S. 1988: Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus Journal of Thoracic and Cardiovascular Surgery 96(2): 242-248
Williams, C.J.; Woods, R.; Levi, J.; Page, J. 1988: Chemotherapy for non-small cell lung cancer: a randomized trial of cisplatin/vindesine v no chemotherapy Seminars in Oncology 15(6 Suppl 7: 58-61
Tsukagoshi, S. 2003: ImmuCyst intravesical (freeze-dried preparation made from the connaught strain of Bacillus Calmette Guérin) for the treatment of superficial bladder cancer and carcinoma in situ of urinary bladder Gan to Kagaku Ryoho. Cancer and ChemoTherapy 30(7): 1027-1038